-
07:25
-07:32
Pembrolizumab vs placebo + paclitaxel ± bevacizumab for platinum-resistant recurrent ovarian cancer: post hoc analysis in the East Asia subgroup of the ENGOT-ov65/KEYNOTE-B96 study
-
07:32
-07:39
First-line niraparib maintenance therapy in BRCA wild-type, low-risk advanced ovarian cancer: the POLO trial
-
07:39
-07:46
BRCA1/2 mutation characteristics and first-line PARP inhibitor maintenance therapy efficacy in advanced ovarian cancer: a multicenter real-world study
-
07:46
-07:53
Surufatinib combined with toripalimab in patients with recurrent ovarian clear cell carcinoma: updated results from a prospective single center, single-arm phase II clinical trial
-
07:53
-08:00
Disitamab vedotin–based therapy in HER2-expressing platinum-sensitive recurrent ovarian, peritoneal, or fallopian tube cancer: DIVERSITY study
-
08:00
-08:07
Final survival outcomes of the OPEB-01/APGOT-OV4 trial and identify clinical and molecular determinants of durable benefit
-
08:07
-08:14
QLS5132, a novel claudin 6-targeting antibody-drug conjugate, in patients with platinum- resistant ovarian cancer: Updated results from a phase 1 trial
-
08:14
-08:21
Final outcomes of dalpiciclib and nonsteroidal aromatase inhibitors (NSAIs) in estrogen receptor-positive (ER+) recurrent/metastatic (R/M) ovarian cancer and uterine neoplasms.

